UNIVERSITÄT ZÜRICH Patent applications |
Patent application number | Title | Published |
20130189363 | BETA-HAIRPIN PEPTIDOMIMETICS - β-Hairpin peptidomimetics of the general formula Cyclo (-Xaa | 07-25-2013 |
20120064541 | N-GLYCAN CORE BETA-GALACTOSYLTRANSFERASE AND USES THEREOF - The present invention relates to new galactosyltransferases, nucleic acids encoding them, as well as recombinant vectors, host cells, antibodies, uses and methods relating thereto. | 03-15-2012 |
20110319291 | TEMPLATE FIXED BETA-HAIRPIN LOOP MIMETICS AND THEIR USE IN PHAGE DISPLAY - Template-fixed β-hairpin mimetics and libraries including a plurality of these mimetics are provided. The template-fixed β-hairpin mimetics are of the following general formula: | 12-29-2011 |
20110245155 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY - Template-fixed β-hairpin peptidomimetics of the general formula (I) | 10-06-2011 |
20110094566 | Luminescence Concentrators and Luminescence Dispersers on the Basis of Oriented Dye Zeolite Antennas - A luminescence concentrator (LK) may concentrate both incident direct and diffuse light by way of frequency shift and total internal reflection. It differs fundamentally from geometric concentrators. With sufficient geometric expansion of the collector plate, nearly arbitrarily high concentration can be achieved in the LK. A luminescence disperser is an apparatus which holds both directional and nondirectional incident light captive in a transparent body by way of frequency shift and total internal reflection and emits it diffusely or directionally uniformly distributed across an area by way of luminescence emission. The object of the invention is a method for the technical implementation of the LK and luminescence disperser, using zeolite crystals having a nanotube structure, into which the luminescent dyes are embedded such that they have antenna properties. Using the resulting novel structures, problems can be solved which made the technical use of LK impossible or at least considerably limited it. This results in completely novel usage possibilities for collecting and concentrating sun light and feeding it into photovoltaic systems, for converting it into electric and thermal energy in combined photovoltaic/hot water apparatuses, and for feeding it into fiber optic apparatuses. | 04-28-2011 |
20110060401 | Tubular Supporting Prosthesis Capable of Growing - The invention relates to a tubular supporting prosthesis capable of growing, comprising a mesh structure, wherein the mesh structure comprises at least two structural rings, which are connected to each other via connecting members and are disposed point-symmetrically about the longitudinal supporting prosthesis axis, wherein the structural rings and/or the connecting members have at least one predetermined breaking point. | 03-10-2011 |
20100121423 | Stent with Vessel Valve - The invention relates to a stent that comprises a single sinus section and is preferably provided at the proximal end thereof with a native vessel valve ( | 05-13-2010 |
20100056432 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY - Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of | 03-04-2010 |
20090295389 | MAGNETIC FIELD PROBE AND METHOD FOR MANUFACTURING THE SAME - A magnetic field probe comprises a sample ( | 12-03-2009 |
20090169602 | Allergy Treatment by Epicutaneous Allergen Administration - The invention provides pharmaceutical compositions, kits, and methods for the treatment of allergy. The compositions are adapted for epicutaneous administration and comprise an allergen and at least one pharmaceutically acceptable excipient. They may be designed as adhesive patches, intradermal delivery devices, ointments, gels, sprays, or similar types of formulation suitable for administration to the skin. Furthermore, the invention provides the use of such compositions in the treatment of allergy. In particular, the compositions are administered to pre-treated skin, wherein the pre-treatment comprises partial or complete dekeratinisation of the epidermis at the selected site of administration. | 07-02-2009 |